Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1067/mva.2003.312 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The Defense Automated Neurobehavioral Assessment (DANA) encompasses a suite of standardized neurocognitive screening tools designed for detecting various neurodegenerative diseases and subtle cognitive deficits. This study presents a pilot investigation into digital cognitive screening, utilizing an Android version of the DANA tests, conducted among a diverse South Asian population residing in India.
Methods: The study involved individuals aged over 50 years, nested within the ongoing population-based longitudinal Precision-CARRS study, representative of socio-demographically and linguistically diverse adults from Delhi and Chennai in India.
Background: Detection of presymptomatic individuals or those with subtle cognitive changes in midlife may prevent or slow the course of Alzheimer's Disease by identifying candidates for disease-modifying treatments. Utilizing newer delivery approaches involving digital measures shows promise for cognitive phenotyping, early detection, ease of administration, and scoring, particularly in low-resource settings. However, the feasibility of these approaches, along with their association with demographics and their effectiveness in detecting fine-grained aspects of cognitive performance in low-resource settings, remains unclear.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Institute for Neurodegenerative Diseases (IND) Florida, Boca Raton, FL, USA.
Background: Alzheimer's disease (AD), Dementia with Lewy Bodies (DLB), and other neurodegenerative diseases (NDD) develop over an extended preclinical period, sharing common risk factors and underlying pathophysiological mechanisms. Plasma proteins, including Amyloid-beta peptides (Aβ) and Tau isoforms, facilitate differential diagnosis of NDD in their earliest stages, allowing for timely delivery of targeted interventions. Blood-based biomarkers may also serve as a reliable means of monitoring disease progression and evaluating the effectiveness of individualized interventions across the spectrum of disease.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Nova Southeastern University, Fort Lauderdale, FL, USA.
Background: Cerebral amyloid angiopathy (CAA), the accumulation of amyloid proteins in the cerebral vasculature, increases the risk of stroke and vascular cognitive impairment and dementia (VCID). Not only is there no treatment for CAA, but the condition is also highly comorbid with Alzheimer's disease (AD), and its presence may serve as a contraindication to treating patients with anti-amyloid therapies due to an increased risk of hemorrhage and edema. Therefore, it is crucial to identify novel treatments for individuals with CAA.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is a neurodegenerative disorder without a cure. Targeting this multifactorial disease by repurposing FDA approved drugs serves as a faster mode of treatment due to its pre-established human safety. We tested terazosin (TZ), an a-1 adrenergic receptor (AR) antagonist and phosphoglycerate kinase-1 (PGK1) activator as having potential to treat AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!